Neurodon Corporation
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Feb 20 to 22, 2027 · next Feb 20
- 1 fee due May 28, 2027The maintenance fee for Quinolines that modulate SERCA and their use for treating disease (US 11,827,626) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
- 1 fee due Aug 6, 2027The maintenance fee for Quinolines that modulate SERCA and their use for treating disease (US 11,890,279) comes due Aug 6, 2027. Unpaid by Feb 7, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,772,881 | Quinolines That Modulate Serca and Their Use for Treating Disease In force · Medium confidence | In force | Medium confidence | |
| US 11,730,729 | Quinolines That Modulate Serca and Their Use for Treating Disease In force · High confidence | In force | High confidence | |
| US 11,827,626 | Quinolines that modulate SERCA and their use for treating disease In force · USPTO record | In force | USPTO record | |
| US 11,992,487 | Quinolines That Modulate Serca and Their Use for Treating Disease In force · Medium confidence | In force | Medium confidence | |
| US 12,144,806 | Quinolines That Modulate Serca and Their Use for Treating Disease In force · Medium confidence | In force | Medium confidence | |
| US 10,383,867 | Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders In force · USPTO record | In force | USPTO record | |
| US 10,730,839 | Quinolines as cytoprotective agents In force · USPTO record | In force | USPTO record | |
| US 10,793,558 | Quinoline oxadiazoles as cytoprotective agents In force · USPTO record | In force | USPTO record | |
| US 10,800,766 | Quinoline alkenes as cytoprotective agents In force · USPTO record | In force | USPTO record | |
| US 10,383,868 | Quinoline containing compounds and their use for treating endoplasmic reticulum stress-related diseases In force · USPTO record | In force | USPTO record |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending